Navigation Links
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
Date:5/15/2008

han 50 mL/min.

Avoid Pregnancy

REBETOL therapy should not be started until a report of a negative pregnancy test has been obtained immediately prior to planned initiation of therapy. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients during therapy and 6 months post- treatment. Patients should use at least two effective forms of contraception and have monthly pregnancy tests during therapy and for 6 months after completion of therapy. A Ribavirin Pregnancy Registry has been established to monitor maternal-fetal outcomes of pregnancies in female patients and female partners of male patients exposed to ribavirin during treatment, and for 6 months following cessation of treatment. Physicians and patients are encouraged to report such cases by calling 1-800-593-2214.

Incidence of Adverse Events

There are no new adverse events specific to PEGINTRON as compared to INTRON A; however, the incidence of some (e.g., injection site reactions, fever, rigors, nausea) were higher. The most common adverse events associated with PEGINTRON were "flu-like" symptoms, occurring in approximately 50% of patients, which may decrease in severity as treatment continues. Application site disorders were common (47%), but all were mild (44%) or moderate (4%) and no patient discontinued, and included injection site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving PEGINTRON. Alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON.

Psychiatric adverse events, which include insomnia, were common (57%) with PEGINTRON but similar to INTRON A (58%). Depression was most common at 29%. Suicidal behavior including ideation, suicidal attempts, and completed suicides occurred in 1% of patients during or shortly after completing treatment with PEGINTRON.

The following serious or clinically sign
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
2. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
3. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
4. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
7. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
8. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
9. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
10. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
11. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 Research and ... Products - Global Strategic Business Report" report to their ... for Anti-Adhesion Products in US$ Thousands by the following three ... Procedures. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ...
(Date:8/18/2014)... and HERZLIYA-PITUACH, Israel , Aug. ... OMX First North Premier, Stockholm : "IMNP"), ... that its application to list its common stock on the ... Market, a unit of the NASDAQ OMX Group. IMMUNE,s common ... Market at the opening of trading on August 21, 2014 ...
(Date:8/18/2014)... 2014 Reportlinker.com announces that a new market ... Russia Sinuscopes Market Outlook to 2020 ... Market Outlook to 2020 Summary ... 2020", provides key market data on the Russia Sinuscopes ... dollars, volume (in units) and average prices (in US ...
Breaking Medicine Technology:Global Anti-Adhesion Products - Strategic Business Report 2014 2Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 2Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 3Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 4Russia Sinuscopes Market Outlook to 2020 2Russia Sinuscopes Market Outlook to 2020 3Russia Sinuscopes Market Outlook to 2020 4
... , SCOTTSDALE, Ariz. , Jan. 22 Matrixx Initiatives, ... financial results for the fiscal 2010 third quarter, ended December 31, ... January 25, 2010 . An earnings conference call will be held the ... AM ET . , To access the teleconference, please call (888) 452-4006 ...
... ... Called Ampyra, to Improve Walking for People With All Types of ... The U.S. Food and Drug Administration has approved the ... Therapeutics) for its ability to improve walking speed in people with ...
Cached Medicine Technology:Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2010 Financial Results 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 4Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 5Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 6
(Date:8/19/2014)... August 20, 2014 LunaDress, a popular ... cocktail dresses for ladies, is now providing a discount ... dresses . The company’s cheap white prom outfits are ... backless, and A-line outfits. , There are over ... product category, and the special offer is valid until ...
(Date:8/19/2014)... Los Angeles, CA (PRWEB) August 19, 2014 ... is an online training course designed to provide users ... businesses using proven email marketing techniques and strategies. The ... has created a buzz of excitement throughout the internet ... caught the attention of HonestyFirstReviews.com's Tiffany Hendricks prompting an ...
(Date:8/19/2014)... HealthDay Reporter TUESDAY, Aug. 19, ... infant has long been linked to development of asthma and ... risk may persist into the teen years. The study, ... underscores the dangers of parental smoking, experts say. ... a child,s risk of developing allergic disease even up to ...
(Date:8/19/2014)... Following the completion of a $16 million rooms renovation ... proud to debut the highly anticipated final phase of its ... of all public spaces to match the fresh look and ... dining experience at 1823 Kitchen and Bar and an innovative ... of 1823 Kitchen and Bar, Grand Hyatt Tampa Bay has ...
(Date:8/19/2014)... Program has selected three geriatric social work ... development and mentorship for projects that will improve ... for all older adults. , The 2014 Hartford/VA ... among veterans, transitions from VA nursing facilities back ... older veterans. The Hartford/VA Geriatric Scholars Program provides ...
Breaking Medicine News(10 mins):Health News:Popular Supplier LunaDress Providing an Exclusive Assortment of White Prom Dresses at a Discount of Up to 67% 2Health News:Anik Singal’s “Inbox Blueprint” Review Released By HonestyFirstReviews.com 2Health News:For Kids, Risks of Parental Smoking Persist Long-Term, Study Finds 2Health News:For Kids, Risks of Parental Smoking Persist Long-Term, Study Finds 3Health News:Grand Hyatt Tampa Bay Hotel Unveils the Finishing Touches of Its $20 Million Makeover 2
... Oct. 4 The following is a,statement regarding Microsoft,s ... information online:, It is encouraging that companies like ... health record (PHR) products and systems,that people can use ... companies will follow suit. Having ready access to your ...
... Orr, fired for managing diabetes at work but ... Thursday before House Judiciary,Subcommittee about his experience, ... today reiterated its strong support for the ADA,Restoration ... the landmark,1990 Americans with Disabilities Act. On Thursday, ...
... ACTON, Mass., Oct. 4 Psychemedics Corporation,(AMEX: ... joined the company,as Vice President, Controller. Jennifer ... financial,reporting activities, as well as the financial analysis ... Jennifer will,report directly to the Chairman and CEO. ...
... Connector, provides patients with virtual diabetes health- ... management ... Association today unveiled a new web-based diabetes tool that,makes it ... -- to,share and organize important health information to improve their ...
... BOSTON, Oct. 4 Diet.com has joined ... of the newly launched Microsoft,HealthVault consumer health ... which currently include,Diet.com Calorie/Meal Tracker, Diet.com Weight ... incorporated into HealthVault. The trackers will,enable users ...
... Oct. 4 Genta,Incorporated (Nasdaq: GNTA ) announced ... Raymond P. Warrell, Jr., will provide an,update of corporate ... 10th at 2:15 pm PDT. The conference will be ... The presentation will be webcast and accessible at the ...
Cached Medicine News:Health News:Statement Regarding Microsoft's Announcement of New Services to Help People Store Their Health Information Online 2Health News:American Diabetes Association Urges Congress to Pass ADA Restoration Act, Help End Employment Discrimination Against Americans with Diabetes 2Health News:American Diabetes Association Urges Congress to Pass ADA Restoration Act, Help End Employment Discrimination Against Americans with Diabetes 3Health News:Jennifer Chmieleski Joins Psychemedics Corporation as Top Financial Officer 2Health News:New Diabetes Tool Available on American Diabetes Association Web Site 2Health News:New Diabetes Tool Available on American Diabetes Association Web Site 3Health News:New Diabetes Tool Available on American Diabetes Association Web Site 4Health News:Diet.com Enters Strategic Collaboration To Support Microsoft HealthVault 2Health News:Genta to Present at Bio Investor Forum 2007 Conference 2Health News:Genta to Present at Bio Investor Forum 2007 Conference 3
... doubled Nd:YAG laser is mounted on Haag ... selected between 0.2 and 2.0 mJ. The ... and 700 microns. Knobs for laser energy ... on the laser head. The laser system ...
... Tango ophthalmic laser system provides two lasers ... and a photodisruptor for posterior capsulotomy and ... Nd:YAG producing pulsed 532 nm light. The ... nm. The appropriate laser can be easily ...
... Glaucoma Laser System features a patented technique ... glaucoma. It selectively targets pigmented cells and ... Selecta II is equipped with a Q-switch ... light, which induces the same cell replacement ...
Thin and smooth jaws, designed to enter trough 3 mm incision, cross action....
Medicine Products: